Advertisement
Organisation › Details
Cerenis Therapeutics S.A.
Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of novel HDL therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary facilitator of the reverse lipid transport, or RLT, pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body. Cerenis is developing a portfolio of HDL therapies, including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients, and HDL elevators for patients with low HDL. Cerenis is well positioned to become the leader in the HDL therapeutic market with a broad portfolio of programs in development. Since its inception in 2005, the company raised €117 million in equity with top tier investors: Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures, Daiwa Corporate Investment, TVM Capital, Orbimed, IRDI/IXO Private Equity and the FSI (Fund for Strategic Investment). €10.7 million were also provided by OSEO, the French agency for innovation, to support the development of CER-001. About CER-001 CER-001, a complex of recombinant human ApoA-I and phospholipids, is being developed for the treatment of patients with acute coronary syndrome. CER-001 is designed to mimic pre-beta HDL, the "good" cholesterol, to promote the removal of excess cholesterol and other lipids from artery walls and enhance reverse lipid transport. *
Start | 2005-03-24 established | |
End | 2019-08-29 renamed | |
Group | Abionyx (Group) | |
Today | Abionyx Pharma S.A. (Euronext Paris: ABNX) | |
Successor | Abionyx Pharma S.A. (Euronext Paris: ABNX) | |
Industry | cardiovascular drug | |
Industry 2 | CER-001 (Cerenis) | |
Person | Dasseux, Jean-Louis (Cerenis Therapeutics 200508 CEO + Pres) | |
Person 2 | Tupin, Cyrille (Abionyx 201909– CEO before Deputy CEO + CFO of predecessor Cerenis Therapeutics) | |
Region | Labège | |
Country | France | |
Street | 265 Rue de la Découverte BP 87519 | |
City | 31675 Labège | |
Tel | +33-5-6224-9706 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
Currency | EUR | |
Cash | 21,500,000 (2017-05-31) | |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Abionyx (Group)
- [1] Abionyx Pharma S.A.. (7/13/23). "Press Release: Abionyx Pharma Announces the Appointment of Laurent Guerci as Chief Digital & Innovation Officer". Toulouse & Lakeland, MI....
- [2] Abionyx Pharma S.A.. (9/9/19). "Press Release: Cyrille Tupin Appointed CEO". Toulouse & Lakeland, US....
- [3] Abionyx Pharma S.A.. (8/27/19). "Press Release: Change of Name and Stock Symbol/Mnemonic of Abionyx Pharma Shares (formerly Cerenis Therapeutics) as of August 29, 2019". Toulouse & Lakeland, US....
- [4] Cerenis Therapeutics S.A.. (4/17/19). "Press Release: Cerenis Therapeutics Has Decided to Terminate the Proposed Merger with H4Orphan Pharma". Toulouse....
- [5] Cerenis Therapeutics S.A.. (3/27/19). "Press Release: Cerenis Therapeutics and H4Orphan Pharma Enter into Exclusive Negotiations to Consider a Strategic Merger". Toulouse....
- [6] Cerenis Therapeutics S.A.. (1/24/19). "Press Release: 2018 Annual Results and Clinical Update". Toulouse & Lakeland, US....
- [7] Cerenis Therapeutics S.A.. (11/8/17). "Press Release: Cerenis Therapeutics Acquires Lypro Biosciences Expanding Its HDL Strategy into Immuno-oncology and Chemotherapeutic Drug Delivery". Toulouse & Lakeland, US....
- [8] Cerenis Therapeutics S.A.. (6/20/17). "Press Release: Bpifrance Supports the Clinical Development of CER-209 in NAFLD /NASH with a €0.75 Million Payment for Innovation". Toulouse & Ann Arbor, MI....
- [9] Cerenis Therapeutics S.A.. (3/1/17). "Press Release: Cerenis Therapeutics Announces Top Line Results of CARAT Phase II Study. No Statistical Difference Observed between CER-001 and Placebo". Toulouse & Ann Arbor, MI....
- [10] Cerenis Therapeutics S.A.. (2/17/16). "Press Release: 2016 Annual Results. Solid Cash Position of €24.7 million and Finalization of CARAT Phase 2 Clinical Study". Toulouse & Ann Arbor, MI....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top